New Horizons in HER2+ Breast Cancer: Pharmacist-Focused Strategies and Insights

Activity Details
  • Credit Amounts:
    • CPE: 1.00
    • Other: 1.00
  • Cost: Free
  • Release: Apr 13, 2020
  • Expires: Apr 13, 2021
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    ( Ratings)


Val R.  Adams Val R. Adams, PharmD, FCCP, BCOP
University of Kentucky College of Pharmacy Markey Cancer Center
Lexington, Kentucky

Neelima  Denduluri Neelima Denduluri, MD
Virginia Cancer Specialists
Reston, Virginia

Target Audience

This activity is designed to meet the educational needs of oncology pharmacists, pharmacy directors, and pharmacy residents.


At the conclusion of this application-based activity, participants will be able to:

  1. Describe the molecular heterogeneity of breast cancer and review how novel treatment approaches such as antibody-drug conjugates (ADCs) are overcoming obstacles in the management of HER2+ disease.
  2. Examine the safety and efficacy profiles of currently-approved ADCs, both in breast cancer and across other malignancies, and evaluate emerging clinical data for agents in late-stage trials.
  3. Explore current guideline recommendations for the management of HER2+ breast cancer and identify key inflection points in the changing treatment paradigm, including resistance mitigation strategies, novel mechanisms, and toxicity prevention.
  4. Using a case-based format, assess challenging clinical questions related to the integration of ADCs into practice, and discuss adaptive ways the oncology pharmacist can optimize therapy, anticipate adverse events, and improve outcomes for patients. 



In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This application-based activity is approved for 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit (UAN JA0007101-0000-20-012-H01-P).

Creative Educational Concepts, Inc. certifies this activity for 1.00 hour of participation.

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.


Val R. Adams, PharmD, FCCP, BCOP–has disclosed that he is a consultant for Amgen.

Neelima Denduluri, MD–has disclosed that she is a consultant for Daiichi Sankyo and Seattle Genetics. She receives grant/research support from Amgen, Daiichi Sankyo, Genentech, Immunomedics, Lilly, Novartis, Pfizer, Seattle Genetics, and Synthon.

 Content Reviewer:

Jason Bergsbaken, PharmD, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.


Presented by Creative Educational Concepts, Inc. (CEC) and supported through independent educational grants from AstraZeneca and Daiichi Sankyo.